Our case must be distinguished from malignant mixed mullerian tumour which occurs in the same age group and has carcinomatous and sarcomatous components. However, these tumours are generally solid, lack the characteristic squamous epithelial lined cyst and show different mucin expression. Immature malignant teratoma occurs in a younger age group and shows a variety of lines of mesenchymal differentiation, notably towards neural elements, which were absent in this case.
Germ cell tumours of all types derive from neoplastic totipotent stem cells whose progeny retain the ability to differentiate towards tissues of all three embryonic somatic layers and the transitional extraembryonal structures. The original pattern of the better differentiated members of this group suggests that local cellular influences are important in determining the final phenotype expressed by individual cells. The histological behaviour and histological appearances of these tumours are determined by the degree to which this embryogenetic environmental responsiveness is retained. In contrast, our case resembles carcinosarcomas at other sites in that there was an essentially random mixture of stromal and epithelial elements. This reflects a probabilistic commitment of individual cells and clones to one or other expressed phenotype without regard to organogenetic influences. Our case implies glandular malignant transformation within the previously benign, fully differentiated, glandular component of a mature cystic teratoma, although no premalignant changes were identified despite thorough sampling.
Adenocarcinomas are the second most common malignancies arising within dermoid cysts' and may display gastrointestinal phenotypes, but lack the malignant stroma as in our case. Sarcomas alone or in combination with squamous carcinoma5 6 have been described arising in a mature cystic teratoma. To the best of our knowledge, no case of sarcoma arising in association with adenocarcinoma has been described before. The extent of the tenascin positive zone in relation to the morphology of the lesion, the presence or absence of HPV DNA and the degree of inflammation is shown in tables 1 and 2. There was no statistically significant difference in the extent of tenascin immunoreactivity between the different CIN lesions. Patients with no or weak inflammation showed significandy less tenascin immunoreactivity (91.5 ± 114.0 pm) than those with strong inflammation (185.5 ± 175.5 pm) (p = 0.002, Fisher's exact test).
There was no significant difference in tenascin inimunoreactivity between patients with benign (71.0 ± 93.0pm) and malignant (88.5 ± 84.5pm) HPV subtypes (p = 0.84, Fisher's exact test). According to a three-way analysis of variance, inflammation had a statistically significant (p = 0.03) effect on the accumulation of tenascin but not on the degree of dysplasia (p = 0.25) or the HPV subtype (p = 0.44).
In the 10 cases studied by in situ hybridisation for tenascin mRNA, labelling was ob- containing HPV DNA. However, in their study, only in a subset of samples were probed for HPV DNA and no definite conclusions could be drawn as to whether it is the degree of dysplasia, HPV subtype or some other factor that was responsible for the enhanced expression of tenascin. In the present study in which in situ hybridisation and dot blot hybridisation were carried out on a large number of cases, we showed conclusively that tenascin accumulation is mainly due to the inflammatory component of these lesions. Consequently, tenascin cannot be used as a marker of the biological potential of dysplastic cervical lesions.
Tenascin cDNA was kindly provided by Dr Luciano Zardi, Instituto Nazionale Per La Ricerca Sul Cancro, Genova, Italy. 
